Insider Transactions Reported by 9 Insiders of BELITE BIO, INC

Symbol: BLTE on Nasdaq
Location: San Diego, CA

Quick Takeaways

BLTE - BELITE BIO, INC has 9 insiders with reported activity on this page.
Net insider value flow over the last year: -$5,666,629.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $5,666,629.
Net share flow: -33,166.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$5,666,629.

Buys

Shares: 0

Insiders: 0

Sells

$5,666,629

Shares: 33,166

Insiders: 4

Net

-$5,666,629

Shares: -33,166

Insiders: -4

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	33,166	$0	$5,666,629	-$5,666,629
3-6	0	$0	$0	$0
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

BELITE BIO, INC executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Yu-Hsin Lin	Chief Executive Officer, Director	$60,450,859	-$1,669,339	-2.7%	Mixed	21 Apr 2026
Hao-Yuan Chuang	Chief Financial Officer, Director	$49,900,932	-$1,125,303	-2.2%	Mixed	21 Apr 2026
Hendrick Peter Scholl	Chief Medical Officer	$6,599,250			Mixed	21 Apr 2026
Wan-Shan Chen	Director	$6,065,140	-$198,473	-3.2%	Mixed	09 Apr 2026
Nathan L. Mata	Chief Scientific Officer	$3,142,374	-$2,673,514	-46%	Mixed	07 May 2026
Xiao-Hui Chen	Director				Mixed	18 Mar 2026
John Michael Longo	Director				Mixed	18 Mar 2026
Ita Lu	Director				Mixed	18 Mar 2026
Gary Clark Biddle	Director				Mixed	18 Mar 2026

Top shareholders of BELITE BIO, INC (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Lin Bioscience International Ltd.	13D/G	—	54%	17,095,263	$1,065,034,885	$0	31 Dec 2024	13D/G
Darwin Global Management, Ltd.	13F 13D/G	Company	8.1% from 13D/G	3,027,704	$486,915,357	—	31 Dec 2025	13F 13D/G
Yu-Hsin Lin	13D/G 3/4/5	Chief Executive Officer, Director	7.1%	2,287,070	$142,484,461	$0	31 Dec 2024	13D/G 3/4/5
RTW INVESTMENTS, LP	13F	Company	1.9%	715,332	$114,424,507	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.5%	558,882	$89,398,765	—	31 Dec 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	1.2%	432,484	$69,180,141	—	31 Dec 2025	13F
PERCEPTIVE ADVISORS LLC	13F	Company	1.1%	414,239	$66,261,670	—	31 Dec 2025	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	1%	383,091	$61,279,236	—	31 Dec 2025	13F
Hao-Yuan Chuang	3/4/5	Chief Financial Officer, Director	— mixed-class rows	588,800 mixed-class rows	$49,900,932	-$1,125,303	21 Apr 2026	3/4/5
Point72 Asset Management, L.P.	13F	Company	0.76%	284,437	$45,498,543	—	31 Dec 2025	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	0.63%	233,813	$37,400,727	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.52%	192,700	$30,824,292	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.34%	128,752	$20,595,170	—	31 Dec 2025	13F
MPM BioImpact LLC	13F	Company	0.23%	87,760	$14,038,090	—	31 Dec 2025	13F
Holocene Advisors, LP	13F	Company	0.22%	84,067	$13,447,357	—	31 Dec 2025	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.21%	79,394	$12,699,864	—	31 Dec 2025	13F
Western Standard LLC	13F	Company	0.16%	60,026	$9,601,759	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.12%	44,599	$7,134,056	—	31 Dec 2025	13F
Hendrick Peter Scholl	3/4/5	Chief Medical Officer	— mixed-class rows	45,000 mixed-class rows	$6,599,250	—	21 Apr 2026	3/4/5
Soleus Capital Management, L.P.	13F	Company	0.11%	40,354	$6,455,026	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.11%	39,839	$6,372,646	—	31 Dec 2025	13F
Wan-Shan Chen	3/4/5	Director	— mixed-class rows	46,355 mixed-class rows	$6,065,140	-$198,473	09 Apr 2026	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.09%	32,318	$5,169,587	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.07%	28,013	$4,480,960	—	31 Dec 2025	13F
Squadron Capital Management LLC	13F	Company	0.07%	26,000	$4,158,960	—	31 Dec 2025	13F
Quadrature Capital Ltd	13F	Company	0.07%	24,832	$3,972,127	—	31 Dec 2025	13F
SUPERSTRING CAPITAL MANAGEMENT LP	13F	Company	0.07%	24,703	$3,951,492	—	31 Dec 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.05%	20,000	$3,199,200	—	31 Dec 2025	13F
PFM Health Sciences, LP	13F	Company	0.05%	19,823	$3,170,887	—	31 Dec 2025	13F
Nathan L. Mata	3/4/5	Chief Scientific Officer	— mixed-class rows	284,600 mixed-class rows	$3,142,374	-$2,673,514	07 May 2026	3/4/5
Woodline Partners LP	13F	Company	0.05%	18,041	$2,885,838	—	31 Dec 2025	13F
Artia Global Partners LP	13F	Company	0.05%	17,989	$2,877,520	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.04%	15,740	$2,517,770	—	31 Dec 2025	13F
BANK OF MONTREAL /CAN/	13F	Company	0.04%	15,538	$2,498,821	—	31 Dec 2025	13F
Exome Asset Management LLC	13F	Company	0.04%	14,328	$2,291,907	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.04%	13,221	$2,114,832	—	31 Dec 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.03%	11,897	$1,903,044	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.03%	10,445	$1,670,782	—	31 Dec 2025	13F
STEMPOINT CAPITAL LP	13F	Company	0.02%	9,163	$1,465,713	—	31 Dec 2025	13F
Seven Fleet Capital Management LP	13F	Company	0.02%	9,161	$1,465,394	—	31 Dec 2025	13F
HRT FINANCIAL LP	13F	Company	0.02%	8,164	$1,305,000	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.02%	6,198	$991,432	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.01%	5,055	$808,598	—	31 Dec 2025	13F
SmartHarvest Portfolios, LLC	13F	Company	0.01%	4,184	$669,273	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.01%	4,176	$667,993	—	31 Dec 2025	13F
High Net Worth Advisory Group LLC	13F	Company	0.01%	3,500	$559,860	—	31 Dec 2025	13F
PSP Research LLC	13F	Company	0.01%	3,443	$550,742	—	31 Dec 2025	13F
Y-Intercept (Hong Kong) Ltd	13F	Company	0.01%	3,152	$504,194	—	31 Dec 2025	13F
PRELUDE CAPITAL MANAGEMENT, LLC	13F	Company	0.01%	3,119	$498,915	—	31 Dec 2025	13F
Arrowpoint Investment Partners (Singapore) Pte. Ltd.	13F	Company	0.01%	3,049	$487,718	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for BELITE BIO, INC

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Nathan L. Mata	BLTE	American depositary share	Sale	-100%	$102,039	$153.21	-666	0	07 May 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-60%	$153,839	$153.84	-1,000	666	06 May 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-37.5%	$155,502	$155.50	-1,000	1,666	05 May 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-27.3%	$155,636	$155.64	-1,000	2,666	04 May 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-21.4%	$155,778	$155.78	-1,000	3,666	01 May 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-17.6%	$156,973	$156.97	-1,000	4,666	30 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-15%	$155,817	$155.82	-1,000	5,666	29 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-13%	$159,162	$159.16	-1,000	6,666	28 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-11.5%	$162,641	$162.64	-1,000	7,666	27 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-10.4%	$159,556	$159.56	-1,000	8,666	24 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-9.38%	$166,284	$166.28	-1,000	9,666	23 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-8.57%	$170,384	$170.38	-1,000	10,666	22 Apr 2026	Direct
Yu-Hsin Lin	BLTE	Ordinary Share	Other	5.78%			10,000	182,949	21 Apr 2026	Direct
Hendrick Peter Scholl	BLTE	Stock Option (right to buy)	Other				10,000	10,000	21 Apr 2026	By Bioptima Ltd.
Hao-Yuan Chuang	BLTE	Ordinary Share	Other	5.12%			10,000	205,264	21 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-7.9%	$166,000	$166.00	-1,000	11,666	21 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-7.32%	$163,595	$163.59	-1,000	12,666	20 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-6.82%	$161,630	$161.63	-1,000	13,666	17 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-6.38%	$160,381	$160.38	-1,000	14,666	16 Apr 2026	Direct
Nathan L. Mata	BLTE	American depositary share	Sale	-6%	$168,298	$168.30	-1,000	15,666	15 Apr 2026	Direct
Yu-Hsin Lin	BLTE	American depositary share	Sale	-5.11%	$1,669,339	$181.45	-9,200	170,934	09 Apr 2026	Direct
Wan-Shan Chen	BLTE	American depositary share	Sale	-10.8%	$198,473	$180.43	-1,100	9,096	09 Apr 2026	Direct
Hao-Yuan Chuang	BLTE	American depositary share	Sale	-6.2%	$1,125,303	$181.50	-6,200	93,800	09 Apr 2026	Direct
Wan-Shan Chen	BLTE	Stock Option (right to buy)	Award				13,796	13,796	31 Mar 2026	Direct
Hao-Yuan Chuang	BLTE	Stock Option (right to buy)	Award	100%			144,868	289,736	31 Mar 2026	Direct
Nathan L. Mata	BLTE	Stock Option (right to buy)	Award	117.7%			144,868	267,934	31 Mar 2026	Direct
Yu-Hsin Lin	BLTE	Stock Option (right to buy)	Award	100%			206,954	413,908	31 Mar 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.